Christian Steidl

Dr. Christian Steidl is an assistant professor in the Department of Pathology at the University of British Columbia, and in Experimental Therapeutics at the BC Cancer Agency (BCCA). He holds an MD from the University of Muenster, Germany, and a PhD-equivalent degree from the University of Witten-Herdecke, Germany. Steidl has expertise in clinical malignant hematology, cytogenetics, molecular genetics, next generation sequencing and functional genomics.

Steidl joined the Centre for Lymphoid Cancer at BCCA in 2006. He is currently supervising a translational research laboratory focusing on the pathogenesis of B cell lymphomas. He is most known for his work on biomarkers in Hodgkin lymphoma and the discovery of novel gene fusions in B cell lymphomas. He has authored 41 refereed articles in the field of hematological malignancies and has been an invited speaker at many conferences. He also serves as a member of the Lymphoma Research Foundation’s Panel of Scientific Advisors and the Cancer Research Society's Medical Expert Committee.

Steidl holds research funding as a principal investigator from the Canadian Institutes of Health Research, the Leukemia and Lymphoma Society of Canada, and the Canadian Hematology Society. He is also co-investigator on a Genome Canada grant to advance personalized treatments of lymphoid cancer patients.


Affiliation

University: University of British Columbia
Faculty: Medicine
Department: Pathology & Laboratory
Position: Assistant Professor
Research Location: BC Cancer Research Centre


Recent Publications

Diefenbach CS, Steidl C. New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments. Clin Cancer Res. 2013 Feb 27. [Epub ahead of print] (PubMed abstract)

Meissner B, Kridel R, Lim RS, Rogic S, Tse K, Scott DW, Moore R, Mungall AJ, Marra MA, Connors JM, Steidl C, Gascoyne RD. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood. 2013 Apr 18;121(16):3161-4. doi: 10.1182/blood-2013-01-478834. Epub 2013 Feb 13. (PubMed abstract)

Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, van den Berg A, Gascoyne RD. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012 Oct 25;120(17):3530-40. doi: 10.1182/blood-2012-06-439570. Epub 2012 Sep 5. (PubMed abstract)

Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011 Mar 17;471(7338):377-81. doi: 10.1038/nature09754. Epub 2011 Mar 2. (PubMed abstract)

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010 Mar 11;362(10):875-85. doi: 10.1056/NEJMoa0905680. (PubMed abstract)